JPH07502483A - 新規ペプチド抗原およびそれを用いるイムノアッセイ、試験キットおよびワクチン - Google Patents
新規ペプチド抗原およびそれを用いるイムノアッセイ、試験キットおよびワクチンInfo
- Publication number
- JPH07502483A JPH07502483A JP3515876A JP51587691A JPH07502483A JP H07502483 A JPH07502483 A JP H07502483A JP 3515876 A JP3515876 A JP 3515876A JP 51587691 A JP51587691 A JP 51587691A JP H07502483 A JPH07502483 A JP H07502483A
- Authority
- JP
- Japan
- Prior art keywords
- htlv
- peptide
- array
- serum
- env
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 175
- 238000003018 immunoassay Methods 0.000 title claims description 30
- 229960005486 vaccine Drugs 0.000 title claims description 13
- 239000000427 antigen Substances 0.000 title description 25
- 102000036639 antigens Human genes 0.000 title description 24
- 108091007433 antigens Proteins 0.000 title description 24
- 238000003149 assay kit Methods 0.000 title description 4
- 210000002966 serum Anatomy 0.000 claims description 114
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 52
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 51
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 241001430294 unidentified retrovirus Species 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 15
- 230000001177 retroviral effect Effects 0.000 claims description 12
- 239000013642 negative control Substances 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000007687 HTLV-II Infections Diseases 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 208000027814 HTLV-2 infection Diseases 0.000 claims 1
- 208000005599 HTLV-I Infections Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005965 immune activity Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 64
- 208000015181 infectious disease Diseases 0.000 description 63
- 230000009257 reactivity Effects 0.000 description 63
- 210000004369 blood Anatomy 0.000 description 56
- 239000008280 blood Substances 0.000 description 56
- 241000282414 Homo sapiens Species 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 47
- 241000700605 Viruses Species 0.000 description 38
- 238000003556 assay Methods 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 28
- 239000000523 sample Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- 238000001514 detection method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 230000000405 serological effect Effects 0.000 description 18
- 241000283707 Capra Species 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 108010010803 Gelatin Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 101800001271 Surface protein Proteins 0.000 description 12
- 101800000385 Transmembrane protein Proteins 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000008273 gelatin Substances 0.000 description 12
- 229920000159 gelatin Polymers 0.000 description 12
- 235000019322 gelatine Nutrition 0.000 description 12
- 235000011852 gelatine desserts Nutrition 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000009260 cross reactivity Effects 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 208000000389 T-cell leukemia Diseases 0.000 description 8
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 7
- 101710091045 Envelope protein Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101710188315 Protein X Proteins 0.000 description 7
- 201000006966 adult T-cell leukemia Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 101150108812 proC gene Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101710121417 Envelope glycoprotein Proteins 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- -1 IDS Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 241000845082 Panama Species 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 101150077062 pal gene Proteins 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 238000012344 serological confirmation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000003156 radioimmunoprecipitation Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 2
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100519160 Arabidopsis thaliana PCR4 gene Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004722 Artley Substances 0.000 description 1
- BKOIIURTQAJHAT-GUBZILKMSA-N Asp-Pro-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 BKOIIURTQAJHAT-GUBZILKMSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 101000805601 Crotalus atrox Zinc metalloproteinase-disintegrin-like atrolysin-A Proteins 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100285402 Danio rerio eng1a gene Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 101001081714 Dictyostelium discoideum Isopentenyl-diphosphate Delta-isomerase Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101710129170 Extensin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000713310 Human T-cell lymphotropic virus type 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 241001163674 Josia Species 0.000 description 1
- 244000162475 Juniperus rigida Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001164593 Merica Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- PHTFSYLVDHSMEH-UHFFFAOYSA-L OO.[Ni](Cl)Cl.NNC1=CC=C(C2=CC=C(NN)C=C2)C=C1 Chemical compound OO.[Ni](Cl)Cl.NNC1=CC=C(C2=CC=C(NN)C=C2)C=C1 PHTFSYLVDHSMEH-UHFFFAOYSA-L 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000012209 assay specification Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000013002 intravenous (IV) drug Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000022638 pyogenic arthritis-pyoderma gangrenosum-acne syndrome Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/574,352 US5378805A (en) | 1990-08-29 | 1990-08-29 | Immunoreactive HTLV-I/II ENV and POL peptides |
| US574,352 | 1990-08-29 | ||
| US73477791A | 1991-07-23 | 1991-07-23 | |
| US734,777 | 1991-07-23 | ||
| PCT/US1991/006214 WO1992004046A1 (fr) | 1990-08-29 | 1991-08-29 | Nouveaux antigenes peptidiques et immunoanalyses, kits de test et vaccins utilisant ces antigenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07502483A true JPH07502483A (ja) | 1995-03-16 |
Family
ID=27076368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3515876A Pending JPH07502483A (ja) | 1990-08-29 | 1991-08-29 | 新規ペプチド抗原およびそれを用いるイムノアッセイ、試験キットおよびワクチン |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0551308A4 (fr) |
| JP (1) | JPH07502483A (fr) |
| AU (1) | AU641554B2 (fr) |
| CA (1) | CA2090470A1 (fr) |
| WO (1) | WO1992004046A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330164T2 (de) * | 1992-02-24 | 2002-01-17 | Genelabs Technologies, Inc. | Htlv-i/htlv-ii assay und verfahren |
| US6406841B1 (en) | 1993-07-01 | 2002-06-18 | Abbott Laboratories | Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| PT1141315E (pt) | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
| CA2634992C (fr) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US9410194B2 (en) * | 2010-06-21 | 2016-08-09 | Life Technologies Corporation | Compositions, kits and methods for synthesis and/or detection of nucleic acids |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02209889A (ja) * | 1988-02-08 | 1990-08-21 | Univ Duke | 合成親水性ペプチド |
| JPH03107764A (ja) * | 1989-09-21 | 1991-05-08 | Nippon Sekijiyuujishiya | 成人型ｔ細胞性白血病関連抗体の測定方法 |
| JPH03127799A (ja) * | 1989-10-13 | 1991-05-30 | Kuraray Co Ltd | ペプチドおよびその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017687A (en) * | 1988-03-10 | 1991-05-21 | Virovahl, S.A. | Peptides for the detection of HTLV-1 infection |
| CA2025019C (fr) * | 1989-01-13 | 2002-06-18 | Chang Yi Wang | Peptides synthetiques reagissant immunologiquement aux anticorps contre le htlv-1 |
| SE8900721D0 (sv) * | 1989-03-02 | 1989-03-02 | Blomberg Jonas | Methods for detection of antibodies to |
| SE467542B (sv) * | 1989-06-13 | 1992-08-03 | Syntello Ab | Syntetiska peptidantigener, immuniserande komposition och immunanalys foer htlv-1 antikroppar |
| ES2072346T3 (es) * | 1989-10-23 | 1995-07-16 | Hoffmann La Roche | Peptidos sinteticos de la cubierta del htlv-i. |
| FI910245A (fi) * | 1990-01-24 | 1991-07-25 | United Biomedical Inc | Syntetiska peptidkompositioner med immunoreaktivitet mot htlv-antikroppar. |
-
1991
- 1991-08-29 WO PCT/US1991/006214 patent/WO1992004046A1/fr not_active Application Discontinuation
- 1991-08-29 AU AU86100/91A patent/AU641554B2/en not_active Ceased
- 1991-08-29 EP EP9191916706A patent/EP0551308A4/en not_active Withdrawn
- 1991-08-29 CA CA002090470A patent/CA2090470A1/fr not_active Abandoned
- 1991-08-29 JP JP3515876A patent/JPH07502483A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02209889A (ja) * | 1988-02-08 | 1990-08-21 | Univ Duke | 合成親水性ペプチド |
| JPH03107764A (ja) * | 1989-09-21 | 1991-05-08 | Nippon Sekijiyuujishiya | 成人型ｔ細胞性白血病関連抗体の測定方法 |
| JPH03127799A (ja) * | 1989-10-13 | 1991-05-30 | Kuraray Co Ltd | ペプチドおよびその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU641554B2 (en) | 1993-09-23 |
| CA2090470A1 (fr) | 1992-03-01 |
| WO1992004046A1 (fr) | 1992-03-19 |
| EP0551308A1 (fr) | 1993-07-21 |
| AU8610091A (en) | 1992-03-30 |
| EP0551308A4 (en) | 1994-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870000702B1 (ko) | 합성 항원 펩티드의 제조방법 | |
| JP2763408B2 (ja) | Ｈｃｖに対する抗体の検出、ｈｃｖ感染の診断及びワクチンとしての予防に有用な合成ペプチド | |
| JP2851278B2 (ja) | Ｈｔｌｖ−ｉに対する抗体の検出のための抗原，ａｔｌのためのワクチンとしてのペプチド組成物およびそれを用いる方法 | |
| Loughran, JR et al. | Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia | |
| DE3752170T2 (de) | Synthetisches Antigen zum Nachweis von mit AIDS in Zusammenhang stehenden Krankheiten | |
| Ferrer et al. | High rate of infection with the human T-cell leukemia retrovirus type II in four Indian populations of Argentina | |
| JPS63196856A (ja) | 改良ペプチド組成物およびｈｔｌｖ−３に対する抗体の検出方法 | |
| US6030769A (en) | Group O HIV-1, fragments of such viruses, and uses thereof | |
| JPS63503513A (ja) | Ｌａｖウィルス変異株、これらのｄｎａおよびタンパク成分ならびに、特に診断目的および免疫原性組成物製造用のそれらの用途 | |
| JPH0751598B2 (ja) | Ｈｔｌｖ‐１感染検出用合成ペプチド抗原 | |
| US6531574B1 (en) | T-lymphotrophic virus | |
| JP3271666B2 (ja) | Ｈｔｌｖ―ｉ、ｈｔｌｖ―ｉｉ又は関連レトロウイルスに対する抗体間の識別、新規ペプチド、抗体の検出及び免疫アッセイキット | |
| JP2818755B2 (ja) | 非ａ非ｂ型肝炎の診断及び検出に有効な新規分枝ハイブリッド及びクラスターペプチド | |
| JP2650217B2 (ja) | Ｈｔｌｖ―１感染の診断、治療及び予防接種のためのペプチド | |
| JPH07502483A (ja) | 新規ペプチド抗原およびそれを用いるイムノアッセイ、試験キットおよびワクチン | |
| JP2643598B2 (ja) | Ｈｔｌｖ‐▲ｉ▼抗体に対する免疫反応性を有する合成ペプチド組成物 | |
| EP0439077B1 (fr) | Composition peptidique ayant une activité immunologique contre des anticorps contre HTLV | |
| PT643835E (pt) | Ensaio e metodo para htlv-i/htlv-ii | |
| US5378805A (en) | Immunoreactive HTLV-I/II ENV and POL peptides | |
| US5476765A (en) | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines | |
| JP2865203B2 (ja) | エイズの原因となる新規なレトロウィルスの抗原の混合物 | |
| WO1993002102A1 (fr) | Nouveaux antigenes de peptides et dosages, kits de tests et vaccins les utilisant | |
| Pestano et al. | Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D | |
| JPS62500592A (ja) | リンパ節症及び後天性免疫不全症候群のウイルスの抗原，特にエンベロ−プ抗原，及びウイルス，ウイルスエンベロ−プ抗原の産生方法，免疫原組成物の調製用叉は該ウイルスに対する抗体の存在の診断用としての該抗原の | |
| JPH02209889A (ja) | 合成親水性ペプチド |